In this 2017 biothreats exercise at Massachusetts General Hospital (MGH), teams participate in a drill on Ebola Virus Disease (EVD).

In October 2018, MGH announced that it would take part in a national, multi -center trial evaluating ZMapp, an experimental treatment consisting of three antibodies to treat EVD. This trial and drills like the one seen here are part of the hospital’s ongoing commitment to being ready and available to care for patients with severe and highly-infectious diseases.

Reblogged 3 months ago from